PULM Pulmatrix Inc.

1.29
-0.06  -4%
Previous Close 1.35
Open 1.34
Price To Book 0.88
Market Cap 10396124
Shares 8,027,895
Volume 276,532
Short Ratio
Av. Daily Volume 896,882

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1H 2019 with data due 2Q 2020.
Pulmazole (PUR1900)
Allergic bronchopulmonary aspergillosis in patients with asthma.
Phase 2a data due 2Q 2020.
PUR1800
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Phase 2 ready.
PUR0200
COPD

Latest News

  1. Pulmatrix to Participate in Upcoming Investor Conferences
  2. Pulmatrix Regains NASDAQ Compliance
  3. These Four Tech Stocks Could Set The Pace On Friday
  4. Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline
  5. Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs
  6. Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
  7. Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
  8. 4 Biotech Stocks Making Moves on Wednesday (2/6/19)
  9. Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1
  10. Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split
  11. Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock
  12. Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock
  13. Pulmatrix, Inc. Announces Proposed Public Offering of Common Stock
  14. Pulmatrix Announces $3.0 Million Registered Direct Offering
  15. Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of Itraconazole
  16. Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology
  17. Pulmatrix Reports Q3 2018 Results